Deprescription on oncological palliative care: an integrating review

Background: Patients on oncologic palliative care (OPC), due to diverse symptomatology and variable severity, tend to present polypharmacy that, although it seems justifiable in many cases, can pose health risks and negative consequences on patients’ quality of life. Thus, it is necessary to evalua...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana P. Antonio, Maria B. Silva, Mariana F. Souza, Maria F. Barbosa
Formato:	article
Lenguaje:	EN PT
Publicado:	Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde 2020
Materias:	Public aspects of medicine RA1-1270 Pharmacy and materia medica RS1-441 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/72ab9045ce7144e6b8f050f58805664f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72ab9045ce7144e6b8f050f58805664f
record_format	dspace
spelling	oai:doaj.org-article:72ab9045ce7144e6b8f050f58805664f2021-11-28T02:45:43ZDeprescription on oncological palliative care: an integrating review10.30968/rbfhss.2019.102.04122179-59242316-7750https://doaj.org/article/72ab9045ce7144e6b8f050f58805664f2020-03-01T00:00:00Zhttps://www.rbfhss.org.br/sbrafh/article/view/412https://doaj.org/toc/2179-5924https://doaj.org/toc/2316-7750 Background: Patients on oncologic palliative care (OPC), due to diverse symptomatology and variable severity, tend to present polypharmacy that, although it seems justifiable in many cases, can pose health risks and negative consequences on patients’ quality of life. Thus, it is necessary to evaluate the presence of possible therapeutic futilities, guiding the process of deprescription, in which there is a reduction in the amount of medication after reviewing the treatment objectives and assessing risks and benefits. Aim: The objective of this study was to identify the main classes of drugs that are candidates for the deprescribing for OPC patients by reviewing the literatura of the last 8 years. Methods: The bibliographic search was performed in the Medline and LILACS databases. Inclusion criteria were articles published between 2010 and 2018, which dealt with the topic of deprescription in CPO. The publications were analyzed for Qualis and the level of scientific evidence, in order to identify the main drugs candidates for deprescription. Results: Twenty articles were evaluated, being only 4 randomized clinical trials (RCTs), with level II of scientific evidence. Among the classes of drugs that are candidates for deprescription, the following stand out: statins (20.37%) and antihypertensives (20.07%). ECRs that corroborate with scientific evidence of quality need to be developed for guidelines that make it possible to prescribe, especially for the population in CPO. Conclusion: We highlight the importance of the use of tools to identify inappropriate medicines, and the use of medication conciliation as a means of identifying them, as well as pharmacotherapeutic follow-up. Ana P. AntonioMaria B. SilvaMariana F. SouzaMaria F. BarbosaSociedade Brasileira de Farmácia Hospitalar e Serviços de SaúdearticlePublic aspects of medicineRA1-1270Pharmacy and materia medicaRS1-441Therapeutics. PharmacologyRM1-950ENPTRevista Brasileira de Farmácia Hospitalar e Serviços de Saúde, Vol 10, Iss 2 (2020)
institution	DOAJ
collection	DOAJ
language	EN PT
topic	Public aspects of medicine RA1-1270 Pharmacy and materia medica RS1-441 Therapeutics. Pharmacology RM1-950
spellingShingle	Public aspects of medicine RA1-1270 Pharmacy and materia medica RS1-441 Therapeutics. Pharmacology RM1-950 Ana P. Antonio Maria B. Silva Mariana F. Souza Maria F. Barbosa Deprescription on oncological palliative care: an integrating review
description	Background: Patients on oncologic palliative care (OPC), due to diverse symptomatology and variable severity, tend to present polypharmacy that, although it seems justifiable in many cases, can pose health risks and negative consequences on patients’ quality of life. Thus, it is necessary to evaluate the presence of possible therapeutic futilities, guiding the process of deprescription, in which there is a reduction in the amount of medication after reviewing the treatment objectives and assessing risks and benefits. Aim: The objective of this study was to identify the main classes of drugs that are candidates for the deprescribing for OPC patients by reviewing the literatura of the last 8 years. Methods: The bibliographic search was performed in the Medline and LILACS databases. Inclusion criteria were articles published between 2010 and 2018, which dealt with the topic of deprescription in CPO. The publications were analyzed for Qualis and the level of scientific evidence, in order to identify the main drugs candidates for deprescription. Results: Twenty articles were evaluated, being only 4 randomized clinical trials (RCTs), with level II of scientific evidence. Among the classes of drugs that are candidates for deprescription, the following stand out: statins (20.37%) and antihypertensives (20.07%). ECRs that corroborate with scientific evidence of quality need to be developed for guidelines that make it possible to prescribe, especially for the population in CPO. Conclusion: We highlight the importance of the use of tools to identify inappropriate medicines, and the use of medication conciliation as a means of identifying them, as well as pharmacotherapeutic follow-up.
format	article
author	Ana P. Antonio Maria B. Silva Mariana F. Souza Maria F. Barbosa
author_facet	Ana P. Antonio Maria B. Silva Mariana F. Souza Maria F. Barbosa
author_sort	Ana P. Antonio
title	Deprescription on oncological palliative care: an integrating review
title_short	Deprescription on oncological palliative care: an integrating review
title_full	Deprescription on oncological palliative care: an integrating review
title_fullStr	Deprescription on oncological palliative care: an integrating review
title_full_unstemmed	Deprescription on oncological palliative care: an integrating review
title_sort	deprescription on oncological palliative care: an integrating review
publisher	Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
publishDate	2020
url	https://doaj.org/article/72ab9045ce7144e6b8f050f58805664f
work_keys_str_mv	AT anapantonio deprescriptionononcologicalpalliativecareanintegratingreview AT mariabsilva deprescriptionononcologicalpalliativecareanintegratingreview AT marianafsouza deprescriptionononcologicalpalliativecareanintegratingreview AT mariafbarbosa deprescriptionononcologicalpalliativecareanintegratingreview
_version_	1718408445308174336

Deprescription on oncological palliative care: an integrating review

Ejemplares similares